Clinical observation of hypofibrinogenemia induced by the treatment of tocilizumab in rheumatic diseases and exploration of risk factor for hypofibrinogenemia-Reference-Cited by-同舟云学术

Clinical observation of hypofibrinogenemia induced by the treatment of tocilizumab in rheumatic diseases and exploration of risk factor for hypofibrinogenemia

Published:2024-03-18 Issue:5 Volume:43 Page:1491-1501
ISSN:0770-3198
Container-title:Clinical Rheumatology
language:en
Short-container-title:Clin Rheumatol

Author:

An Qi,Ma Rulan,Yuan Dawei,Huang Jing,Luo Jing,Wang Yanhua,Pan Ying,Wang Pei,Lv Xiaohong,Pu Dan,He Lan^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10067-024-06937-0.pdf

Reference25 articles.

1. Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T (2020) Translating IL-6 biology into effective treatments. Nat Rev Rheumatol 16:335–345. https://doi.org/10.1038/s41584-020-0419-z

2. Malaviya AP, Ledingham J, Bloxham J et al (2014) The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis. Rheumatology (Oxford) 53:1344–1346. https://doi.org/10.1093/rheumatology/keu168

3. Üsküdar Cansu D, Demirtaş E, Andiç N, Üsküdar Teke H, Korkmaz C (2019) Is it required to routinely check fibrinogen level in patients with rheumatic diseases on tocilizumab? Case-based review Rheumatol Int 39:743–750. https://doi.org/10.1007/s00296-019-04268-x

4. Imamura H, Momohara S, Yano K, Sakuma Y, Nakayama M, Tobimatsu H, Ikari K (2018) Tocilizumab treatment in patients with rheumatoid arthritis is associated with reduced fibrinogen levels and increased blood loss after total knee arthroplasty. Mod Rheumatol 28:976–980. https://doi.org/10.1080/14397595.2018.1428041

5. Okano T, Inui K, Tada M, Sugioka Y, Mamoto K, Wakitani S, Koike T, Nakamura H (2016) Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study. Rheumatol Int 36:349–357. https://doi.org/10.1007/s00296-015-3379-x

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of tocilizumab-induced hypofibrinogenemia in rheumatology practice: a retrospective, real-life, single-center experience;Rheumatology International;2024-09-12

2. Risk factor for hypofibrinogenemia induced by tocilizumab in rheumatic diseases;Clinical Rheumatology;2024-08-24